Nurix Therapeutics, Inc.
NASDAQ:NRIXBiotechnology
Healthcare
$14.10 +0.85%
+$0.15 today
- Market cap
- $1.54B
- Beta
- 1.87
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$2.68
52W Low $8.20High $22.50
Volume 2.79M
Average 1.74M
Income Statement
Follow revenue through to earnings.
Revenue
$83.98M
FY 2025 · Annual
+54.0% YoYOperating Income
-$285.67M
FY 2025 · Annual
Net Income
-$264.46M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Nov 2021 | FY2022 Nov 2022 | FY2023 Nov 2023 | FY2024 Nov 2024 | FY2025 Nov 2025 |
|---|---|---|---|---|---|
| Revenue | 29.75M | 38.63M | 76.99M | 54.55M | 83.98M |
| Cost of Revenue | 116.43M | 184.5M | 189.15M | 221.63M | 18.86M |
| Gross Profit | (86.68M) | (145.87M) | (112.16M) | (167.08M) | 65.12M |
| Gross Margin | -291.4% | -377.6% | -145.7% | -306.3% | 77.5% |
| Research & Development | 116.43M | 184.5M | 189.15M | 221.63M | 308.16M |
| Selling, General & Admin | 31.2M | 38M | 42.9M | 45.94M | 52.74M |
| Operating Expenses | 31.2M | 38M | 42.9M | 45.94M | 350.79M |
| Depreciation & Amortization | 6.08M | 10.81M | 13.65M | 16.43M | 18.86M |
| EBITDA | (110.98M) | (169.55M) | (130.29M) | (176.87M) | (244.84M) |
| EBITDA Margin | -373.0% | -438.9% | -169.2% | -324.2% | -291.5% |
| Operating Income | (117.89M) | (183.87M) | (155.06M) | (213.03M) | (285.67M) |
| Operating Margin | -396.3% | -476.0% | -201.4% | -390.5% | -340.2% |
| Interest Income | 823K | 3.51M | 11.12M | 19.73M | 21.97M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 823K | 3.51M | 11.12M | 19.73M | 21.97M |
| Income Before Tax | (117.06M) | (180.36M) | (143.95M) | (193.3M) | (263.7M) |
| Pre-Tax Margin | -393.5% | -466.9% | -187.0% | -354.4% | -314.0% |
| Income Tax Expense | 131K | 0 | 0 | 270K | 760K |
| Net Income | (117.19M) | (180.36M) | (143.95M) | (193.57M) | (264.46M) |
| Net Margin | -393.9% | -466.9% | -187.0% | -354.9% | -314.9% |
| EPS (Basic) | (2.73) | (3.71) | (2.65) | (2.88) | (3.05) |
| EPS (Diluted) | (2.73) | (3.71) | (2.65) | (2.88) | (3.05) |
| 42.9M | 48.61M | 54.34M | 67.12M | 86.67M | |
| 42.9M | 48.61M | 54.34M | 67.12M | 86.67M |
NRIX Earnings Waterfall · TTM
NASDAQ:NRIX · Revenue to Net Income
Key Ratios
EPS$2.31
Gross Margin-255.7%
Net Margin-719.7%
P/E Ratio-3.6
P/S Ratio154.4
Analysis
$701.9M of revenue converted into $294.9M of net income for the selected period. Gross margin is -255.7% and net margin is -719.7%, showing how much revenue survives after costs and taxes. EPS is $2.31, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 |
How much revenue does NRIX generate?
Nurix Therapeutics, Inc. (NRIX) reported $83.98M of revenue in fiscal 2025.
Is NRIX profitable?
Nurix Therapeutics, Inc. (NRIX) reported -$264.46M of net income, with a net margin of -314.9%.
Continue the stock analysis
Jump to another research area for this company.